Will Your Acquired Compound Pass Inspection?

Paper or digital, Phlexglobal can fix a faulty TMF

group-of-successful-multiethnic-business-people-ce-2022-07-05-00-33-38-utc

Avoid application delays and challenges by getting a true picture of a therapy’s inspection-readiness

In today’s pharmaceutical M&A environment, compounds or molecules that have been through clinical development – sometimes years previously – often end up with new owners. And while the science and market rationale behind these acquisitions are the focus, much less attention is paid to an important practical question: What is the state of the Trial Master File?

Thanks to Phlexglobal’s authoritative TMF expertise and our mastery of eTMF technologies, you can now easily get a true picture of your acquired drug’s readiness for inspection and/or submission.  Whether you’ve received hundreds of boxes of paper documents, gigabytes of data, or some combination, Phlexglobal is the recognized leader in rapidly and accurately converting this often chaotic documentation into a high-quality, inspection-ready TMF.

 

Contact Us

Discover why several Top 50 pharmaceutical companies have turned to Phlexglobal to successfully review and validate TMF documentation for acquired drugs, placing their trust in our proven end-to-end process:

  • Complete inventory of all content and rapid, accurate conversion of documentation to usable, digital format aligned with the TMF Reference model
  • Detailed Quality Review of all documentation, with high-level heatmaps for executive overview and granular line-by-line detail for taking action
  • Full gap analysis to identify missing documentation, together with a risk-based remediation plan
  • Visibility to progress throughout the conversion to the TMF, with early identification and prioritization of critical items for corrective action

Case Study

 

Accelerated Processing

Reducing time to a submission-ready TMF from six months to nine weeks

Phlexglobal helped a Top 20 US pharmaceutical company submit their NDA for an acquired drug weeks ahead of schedule, successfully converting 500 boxes of paper and 500GB of documents – and in 65% less time than the customer anticipated.

Complexity? Our Specialty

Successfully converting >1 million pages of documents from different CROs and in multiple TMF structures

A Top 20 European pharmaceutical company thought they had 250,000 pages of documentation from an acquired drug. It was actually more than one million pages. Even with this 300% increase in scope, Phlexglobal was able to meet their original schedule for building an inspection-ready Trial Master File.

Digital Brain Header Large Brain Right

It's time to raise your standard 

CONTACT PHLEXGLOBAL TODAY
 
Contact Us

Latest News

Five-step Game Plan for a TMF Close-out

Close-out of a clinical trial raises many questions about responsibility and management of the trial master file (TMF). According to ICH E6 (R2), final close-out can only occur when the monitor – or

Key Trends and Hot Topics from the Fierce TMF Summit US

Introduction: Trial Master File (TMF) experts are acutely aware of the growing complexity involved in meeting compliance obligations and improving overall quality and completeness. As those working

Staying on Top of the Trial Master File

As regulatory agencies increasingly focus on the processes and workflows behind the Trial Master File (TMF), not just on what it contains, the pressure has increased on sponsors to ensure theirs is